Table 2.
Univariate logistic regressions for the association of body composition values, toxicity, dose reduction, early discontinuation of chemotherapy, and cycle delays.
| Overall toxicity (n = 64) | Dose reduction (n = 64) | Early discontinuation of chemotherapy (n = 64) | Cycle delays (n = 60) | |||||
|---|---|---|---|---|---|---|---|---|
| OR | z (p-value) | OR | z (p-value) | OR | z (p-value) | OR | z (p-value) | |
| SAT | 1.00 | 0.02 (0.984) |
1.00 | 0.53 (0.597) |
1.00 | 0.76 (0.446) |
1.00 | 0.67 (0.506) |
| VAT | 0.99 | −0.19 (0.851) |
1.00 | 0.55 (0.583) |
1.00 | 0.80 (0.425) |
1.01* | 2.01 (0.044) |
| SMA | 1.01 | 0.63 (0.526) |
1.01 | 0.77 (0.441) |
1.03* | 2.10 (0.036) |
1.02 | 1.57 (0.117) |
| Mean SMD | 0.99 | −0.85 (0.395) |
0.98 | −1.30 (0.192) |
0.99 | −0.62 (0.538) |
0.92** | −2.70 (0.007) |
| SMI | 1.00 | 0.19 (0.846) |
1.01 | 0.30 (0.761) |
1.03 | 1.00 (0.316) |
1.02 | 0.66 (0.51) |
Significance level lower than *0.05, **0.01; p-value reported in parentheses. Significant associations between VAT and SMD with cycle delays, and SMA and early discontinuation of chemotherapy. SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; SMD, skeletal muscle density; SMA, skeletal muscle area; SMI, skeletal muscle index.